Abstract
The Wilms tumor 1 (WT1) gene encodes a transcription factor that was among the first tumor suppressor genes to be identified. Dependent on the splice variant, some WT1 isoforms can function as transcriptional regulators, whereas other WT1 proteins are presumably involved in RNA processing. The mechanisms by which WT1 regulates transcription and the identification of bona fide target genes have been difficult to study, which is partially due to the complex nature of the gene and its context specific functions. While the role of WT1 as a tumor suppressor in Wilms tumor is widely accepted, considerable evidence points to an oncogenic function in other tumors. Recent studies have provided new insights into the underlying mechanisms that lead to the development of Wilms tumor. In addition, a conditional Wt1 knockout mouse model and RNAi-mediated screening approaches have uncovered new functions for WT1 in development and tumorigenesis.
Keywords: Apoptosis, HTRA2, Igf2, oncogene, senescence, WT1, sumoylation, phosporylation, Tumorigenesis, epithelial-mesenchymal
Current Pediatric Reviews
Title: Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis
Volume: 7 Issue: 4
Author(s): Jorg Hartkamp
Affiliation:
Keywords: Apoptosis, HTRA2, Igf2, oncogene, senescence, WT1, sumoylation, phosporylation, Tumorigenesis, epithelial-mesenchymal
Abstract: The Wilms tumor 1 (WT1) gene encodes a transcription factor that was among the first tumor suppressor genes to be identified. Dependent on the splice variant, some WT1 isoforms can function as transcriptional regulators, whereas other WT1 proteins are presumably involved in RNA processing. The mechanisms by which WT1 regulates transcription and the identification of bona fide target genes have been difficult to study, which is partially due to the complex nature of the gene and its context specific functions. While the role of WT1 as a tumor suppressor in Wilms tumor is widely accepted, considerable evidence points to an oncogenic function in other tumors. Recent studies have provided new insights into the underlying mechanisms that lead to the development of Wilms tumor. In addition, a conditional Wt1 knockout mouse model and RNAi-mediated screening approaches have uncovered new functions for WT1 in development and tumorigenesis.
Export Options
About this article
Cite this article as:
Hartkamp Jorg, Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis, Current Pediatric Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339611796892373
DOI https://dx.doi.org/10.2174/157339611796892373 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Lactones: Generic Inhibitors of Enzymes?
Mini-Reviews in Medicinal Chemistry Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Luminescent Carbon Dots
Current Analytical Chemistry Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Current Cancer Drug Targets The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Clinicopathological Significance of Long Non-Coding RNA <i>GHET1</i> in Human Cancers: A Meta-Analysis
Current Pharmaceutical Biotechnology Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Current Molecular Pharmacology Management of Vaginal Cancer
Reviews on Recent Clinical Trials Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal Impact of the Somatotrope Growth Hormone (GH)/Insulin-Like Growth Factor 1 (IGF-1) Axis Upon Thymus Function: Pharmacological Implications in Regeneration of Immune Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry